Effect of alendronate on HIV-associated osteoporosis: A randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120)

AIDS Research and Human Retroviruses

Volumn 28, Issue 9, 2012, Pages 772-780

  Rozenberg, Sylvie ^a   Lanoy, Emillie ^b   Bentata, Michelle ^c   Viard, Jean Paul ^d   Valantin, Marc Antoine ^a,b   Missy, Pascale ^b   Darasteanu, Iuliana ^b   Roux, Christian ^e   Kolta, Sami ^e  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

^c AVICENNE HOSPITAL   (France)

^d HÔTEL DIEU   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIRETROVIRUS AGENT; CALCIUM CARBONATE; PLACEBO; VITAMIN D;

ADRENAL INSUFFICIENCY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE DENSITY; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRON DEFICIENCY ANEMIA; LITHOTRIPSY; LUMBAR SPINE; MALE; OSTEOPOROSIS; OTITIS MEDIA; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSTATITIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT; VIRUS LOAD;

EID: 84863828409     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0224     Document Type: Article

References (29)

1. Amiel C, Ostertag A, Slama L, et al.: BMD is reduced in HIVinfected men irrespective of treatment. J Bone Miner Res 2004;19(3):402-409. (Pubitemid 38787395)
2. Bruera D, Luna N, David DO, et al.: Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003;17(13):1917-1923. (Pubitemid 37070277)
3. Cazanave C, Dupon M, Lavignolle-Aurillac V, et al.: Reduced bone mineral density in HIV-infected patients: Prevalence and associated factors. AIDS 2008;22(3):395-402.
4. Madeddu G, Spanu A, Solinas P, et al.: Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging 2004;48(1):39-48. (Pubitemid 39069663)
5. Tebas P, Powderly WG, Claxton S, et al.: Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000;14(4):F63-67. (Pubitemid 30182458)
6. Brown TT and Qaqish RB: Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006;20(17):2165-2174. (Pubitemid 44684707)
7. Yin MT and Glesby MJ: Low bone mineral density, HIV infection, and women: Fracture or fiction? Clin Infect Dis 2006;42(7):1021-1023.
8. Amorosa V and Tebas P: Bone disease and HIV infection. Clin Infect Dis 2006;42(1):108-114. (Pubitemid 41832089)
9. Mallon PW: Bones of Contention-HIV and Bone Disease. Paper presented at the XVIII International AIDS Conference; July, 18-23, 2010, Vienna.
10. Bolland MJ, Grey AB, Gamble GD, et al.: Low body weight mediates the relationship between HIV infection and low bone mineral density: A meta-analysis. J Clin Endocrinol Metab 2007;92(12):4522-4528. (Pubitemid 350223420)
11. Kanis JA: Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359(9321):1929-1936. (Pubitemid 34615775)
12. Triant VA, Brown TT, Lee H, et al.: Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008;93:3499-3504.
13. Young B, Dao CN, Buchacz K, Baker R, Brooks J, and the HIV Outpatient Study Investigators: Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis 2011;52:1061-1068.
14. Womack JA, Goulet JL, Gibert C, et al.: Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PloS One 2011;6:e17217.
15. Bedimo R, Zhang S, Drechsler H, et al.: Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, July 17-20, 2011. Abstract no. MOAB0101.
16. Bilezikian JP: Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med 2009; 122(2 Suppl):S14-21.
17. Poole KE and Compston JE: Osteoporosis and its management. BMJ 2006;333(7581):1251-1256. (Pubitemid 46043106)
18. Orwoll E, Ettinger M, Weiss S, et al.: Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343(9):604-610. (Pubitemid 30659471)
19. Faulkner KG: Bone densitometry: choosing the proper skeletal site to measure. J Clin Densitom 1998;1(3):279-285. (Pubitemid 128350321)
20. Kolta S, Ravaud P, Fechtenbaum J, et al.: Follow-up of individual patients on two DXA scanners of the same manufacturer. Osteoporos Int 2000;11(8):709-713.
21. McComsey GA, Kendall MA, Tebas P, et al.: Alendronate with Calcium and Vitamin D Supplementation Is Superior to Calcium and Vitamin D Alone in the Management of Decreased Bone Mineral Density in HIV-Infected Patients: Results of ACTG 5163. Paper presented at the 14th Conference on Retroviruses and Opportunistic Infections, February 27-28, 2007, Los Angeles.
22. Lewiecki EM, Watts NB, McClung MR, et al.: Official positions of the international society for clinical densitometry. J Clin Endocrinol Metab 2004;89(8):3651-3655. (Pubitemid 39071449)
23. McComsey GA, Kendall MA, Tebas P, et al.: Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS 2007;21(18):2473-2482. (Pubitemid 350145179)
24. Mondy K, Powderly WG, Claxton SA, et al.: Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr 2005;38(4):426-431. (Pubitemid 40381552)
25. Guaraldi G, Orlando G, Madeddu G, et al.: Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. HIV Clin Trials 2004;5(5):269-277. (Pubitemid 39545399)
26. Negredo E, Martinez-Lopez E, Paredes R, et al.: Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. AIDS 2005;19(3):343-345. (Pubitemid 40396568)
27. Huang J, Meixner L, Fernandez S, et al.: A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS 2009;23(1):51-57.
28. Bolland MJ, Grey AB, Horne AM, et al.: Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab 2007;92(4):1283-1288. (Pubitemid 46556399)
29. Prior J, Burdge D, Maan E, et al.: Fragility fractures and bone mineral density in HIV positive women: A case-control population-based study. Osteoporos Int 2007;18(10):1345-1353. (Pubitemid 47389474)